How Peptidomimetics Are Making 'Undruggable' Disease Targets Treatable
Peptidomimetics — molecules that mimic peptide structure but resist degradation — bridge the gap between small-molecule drugs and biologics, enabling therapeutic targeting of previously 'undruggable' protein-protein interactions.
Quick Facts
What This Study Found
Peptidomimetics — particularly stapled peptides and macrocyclic peptides — have been successfully applied to target numerous 'undruggable' protein-protein interactions, combining the targeting capability of peptides with improved pharmacokinetic properties through conformational constraint.
Key Numbers
How They Did This
Narrative review of chemical approaches for creating conformationally constrained peptidomimetics, focusing on stapled peptides and macrocyclization strategies, with examples of successful biological applications.
Why This Research Matters
Most disease-relevant protein-protein interactions cannot be targeted by conventional small-molecule drugs, creating a vast untapped therapeutic space that peptidomimetics can uniquely address.
The Bigger Picture
Peptidomimetics represent the third wave of drug development — after small molecules and biologics. By occupying the middle ground in size and properties, they can reach therapeutic targets inaccessible to either conventional modality. The concept of 'drugging the undruggable' through constrained peptide-like molecules has moved from academic curiosity to clinical reality, with stapled peptides entering clinical trials for cancer and other diseases. This review captures the field at a pivotal transition from proof-of-concept to therapeutic pipeline.
What This Study Doesn't Tell Us
As a 2018 review, it may not cover the most recent advances in peptidomimetic chemistry and clinical development. The review focuses on chemical approaches without detailed discussion of manufacturing, cost, or clinical translation challenges.
Questions This Raises
- ?Which peptidomimetic platforms are closest to achieving FDA approval for targeting PPIs?
- ?Can AI-driven design accelerate the optimization of peptidomimetic drug candidates?
- ?How will peptidomimetics compete with or complement antibody-based approaches for PPI modulation?
Trust & Context
- Key Stat:
- Targeting the 'undruggable' Peptidomimetics combine peptide-like binding surfaces with drug-like stability, successfully modulating protein-protein interactions that conventional small molecules and biologics cannot reach
- Evidence Grade:
- This is a narrative review covering the chemical and biological aspects of peptidomimetic development. It provides a comprehensive overview of the field but does not present new experimental data.
- Study Age:
- Published in 2018, this review captured the peptidomimetics field during its transition from academic research to clinical development. The field has continued to advance rapidly since publication.
- Original Title:
- Peptidomimetics Targeting Protein-Protein Interactions for Therapeutic Development.
- Published In:
- Protein and peptide letters, 25(12), 1076-1089 (2018)
- Authors:
- Zhang, Gan, Andersen, Jessica, Gerona-Navarro, Guillermo
- Database ID:
- RPEP-04009
Evidence Hierarchy
Frequently Asked Questions
What is a peptidomimetic?
A peptidomimetic is a molecule designed to mimic the shape and function of a natural peptide, but with chemical modifications that make it more drug-like. These modifications can include backbone changes, cyclization (forming rings), or stapling (adding crosslinks) that resist enzymatic degradation, improve cell entry, and extend the molecule's life in the body — addressing the main weaknesses that prevent natural peptides from being good drugs.
Why are protein-protein interactions so hard to target with drugs?
Protein-protein interaction surfaces are typically large (1,500-3,000 square angstroms), relatively flat, and lack the deep pockets that small-molecule drugs need to bind. It's like trying to use a key on a surface that has no keyhole. Peptidomimetics work because they're large enough to cover a significant portion of these flat surfaces while being structured enough to make specific contacts — like a molecular handshake rather than a key-and-lock mechanism.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04009APA
Zhang, Gan; Andersen, Jessica; Gerona-Navarro, Guillermo. (2018). Peptidomimetics Targeting Protein-Protein Interactions for Therapeutic Development.. Protein and peptide letters, 25(12), 1076-1089. https://doi.org/10.2174/0929866525666181101100842
MLA
Zhang, Gan, et al. "Peptidomimetics Targeting Protein-Protein Interactions for Therapeutic Development.." Protein and peptide letters, 2018. https://doi.org/10.2174/0929866525666181101100842
RethinkPeptides
RethinkPeptides Research Database. "Peptidomimetics Targeting Protein-Protein Interactions for T..." RPEP-04009. Retrieved from https://rethinkpeptides.com/research/zhang-2018-peptidomimetics-targeting-proteinprotein-interactions
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.